What's New in Neurofeedback

A Monthly Summary of News and Events

Vol. 7 No. 9 - September 2004

This newsletter is sponsored by EEG Spectrum International Intl, Inc.,
a leader in providing clinical service and training professionals.

Past issues are available at start.eegspectrum.com/Newsletter/
Information on how to subscribe or cancel a subscription appear at the end.
The opinions related in this newsletter reflect those of the author only.
Copyright (C) 2004 by EEG Spectrum International Intl, Inc. All rights reserved.



  • Announcements  - News
  • In the Spotlight     - Take Two Placebos and Call Me in the Morning, revised
  • News & Reviews - Books & journal papers
  • Events & Locations - Conferences, Courses
  • Last Word               - Faulty Foresight

  •  

    Announcements


     

    In the Spotlight

    Take Two Placebos and Call Me in the Morning, revised

    As we learn more about the biological underpinnings of psychological disorders and how conditions such as depression and anxiety rewire our neural circuitry, skewing our reward systems and cognitive apparatus, we will probably need to rethink the distinction between neurological disorders and psychiatric ones and develop a new category, such as psychoneurological disorders; or perhaps pneurological disorders. Although neurofeedback has proven anticonvulsant properties, some critics claim that evidence for treating psychological disorders is lacking, either due to design problems or placebo effects. That anticonvulsants are now regularly used for numerous psychiatric conditions (e.g., bipolar disorder, OCD, PTSD, social phobia, alcohol withdrawal and dependence) makes the neurology/psychiatry distinction tenuous at best. That impact in psychiatric functioning can be so readily prescribed to the placebo effect indicates how layperson knowledge colors scientific understanding about this phenomenon. This is no placebo effect, per se. We are misguided when we ignore the role mental processes play in neurological and psychiatric symptoms, and the history of placebo research is fraught with misconceptions.

    When Freud gave a name to our darkness, the unconscious, he set loose a process of distrust in ourselves and our self-knowledge that may never end. From this infernal creation descends a minion known as the placebo effect, the idea that the mind can make itself better if only each of us allow it. Healing through distraction, or concentration, or surrender. It's a interesting idea, if it works.

    But does it.

    Henry K. Beecher's influential 1955 paper "The Powerful Placebo," published in the Journal of the American Medical Association, was the first study to quantify the magnitude of the placebo effect and it is this paper which is the source of our layperson knowledge. Beecher claimed that about a third (35%) of 1082 patients were "satisfactorily relieved" by a placebo alone. This value was not carved in stone but merely a mathematical average of 15 clinical trials for a variety of diseases. Improvements ranged from 21 to 58 percent, so the reliability of the one-third number (or 35%) should have been questioned from the very start.

    Forty years later, it was questioned. In the Journal of Clinical Epidemiology, Kienle and Kiene (1997) examined all of Beecher's studies and determined that "no evidence was found of any placebo effect in any of the studies cited by (Beecher)." One hundred percent off the mark! Impressive. Instead of a placebo effect, Kienle and Kiene (1997) concluded that the improvements reported in these groups of studies could be accounted for by the following: spontaneous improvement also known as recovery, symptom fluctuation, regression to the mean, concomitant treatments, scaling bias, obliging reports by patients, irrelevant response variables, experimental subordination, conditioned answers, psychosomatic phenomena, and other factors including an "active placebo" also known as an (active) treatment. No room for anything to do with the spooky unconscious (that is, psychological anticipation).

    In a related paper the same authors wonder whether the placebo effect was largely illusory and may not exist at all. It would be a vestige of Freudian thought clinging to our post-modern thought (my words, not theirs). Gotzsche (1995) argued that the concept of placebo should be discarded altogether, but most disagree and continue to argue that psychological mechanisms underlay nonspecific effects (e.g., Kirsch, 1997). Freud, once unloosed, can never die.

    As any physicist can tell you, studying a phenomenon, even one that doesn't have in basis in reality, can be interesting and even fruitful. For a placebo effect to exist, what neurobiological mechanisms must control it, what neuroanatomical or functional systems must be involved? What are the duration and dosage curves like and why? Levine volunteered endorphins to answer some of these questions. Others have gone so far to say that the placebo effect may occasionally be toxic! (cf. Shapiro & Shapiro, 1997; Freud kills). While important questions have yet to be addressed, some researchers in mental health began to sling the term around like mud at anything they did not have patent rights to. Perhaps with hindsight, Kienle and Kiene (1997) warned that "the placebo topic seems to invite sloppy methodological thinking." And sloppy thinking is the hurdle facing any treatment modality which competes (effectively) against the current standard.

    The Ethics of Placebo Controls

    In 1992, Russell Barkley argued that neurofeedback must be compared to the placebo condition before he would take any claim seriously. He suggested using sham feedback in his report (CHADDer Box). Human protection committees and researchers recognize how the "option" of false feedback may be unethical, as well as impractical -- another example of sloppy thinking. False feedback often "breaks the blind" of the patient. Children are particularly quick to detect when information on the monitor is not associated with their EEG. (An interesting finding in and of itself.) This means that a double-blind is unlikely to hold, and remains a fiction as it also exists in much of clinical research. (e.g., if clinicians and researchers involved in a double-blind cannot recognize which patient received the active treatment and which the sugar pill after awhile, then the treatment isn't very effective, is it?)

    The Nuremberg Code formulated shortly after World War II in response to Nazi atrocities limits the extent of future human experimentation and was the precursor to the Declaration of Helsinki accepted by the World Health Organization in 1964, a declaration to which our governmental and regulatory bodies prescribe. The Declaration of Helsinki elevates concern for the health and rights of individual subjects over concern for society, for future patients, or for science.. "In any medical study," it asserts "every patient -- including those of a control group, if any -- should be assured of the best proven diagnostic and therapeutic method." Re-read that statement. It ends the use of placebo controls when a proven therapeutic method exists. A study that violates this provision should not be accepted for publication and any application to a regulatory body for a treatment which unnecessarily involved placebo -controlled trials ought be rejected.

    Ought to be.

    The Code of Federal Regulations under which the FDA operates includes mention of the use of placebo controls, thus deeming them acceptable for US biomedical research. Some researchers complain (in letter to BMJ, etc.) that without a placebo control, their grant proposals will never be funded. Even when alternative treatments are available, a placebo control is an implicit requirement in competitive funding situations. This de facto requirement includes disorders of moderate severity and pain, clearly in violation of the Declaration of Helsinki. Recently, non-inferiority trials have arisen as an alternative to placebo controls; trials in which an experimental treatment may not be superior to an already known active agent but is also not clinically or statistically inferior to that agent in its effectiveness. In this way, a researcher can fulfill their ethical obligation to all patients in a trial. In a sense, both the experimental group and non-experimental group are being providing the best treatment available.

    Why are placebos used at all ?

      I can think of three reasons why placebo controls are desirable:
    1. To evaluate absolute efficacy: Placebo controls supposedly determine whether a new treatment is better than nothing.
    2. To avoid difficult decisions about treatment effectiveness: Differences in cost, unintended (side) effects, drug interactions, and other factors may make comparisons between treatments of similar efficacy inexact and subjective.
    3. To bolster statistical significance: As any psych grad student knows, it is much easier to detect statistical significance between a placebo and an active treatment than between two active treatments. (And it is less expensive to use a placebo condition than to increase the n, the other method of bolstering one's stats.)

    Ignoring the ethics of requiring placebo controls, or even the phenomenological argument of whether placebo effects exist at all, I think we can distinguish a placebo from an active treatment by the following criteria:

    1. Specificity: A single symptomalogical or functional domain is impacted by a treatment compared to nonspecific or multiple domains (This one will be difficult with neurofeedback as the functional improvement is regulatory, not focal.)
    2. Toxicity: Use of the treatment can cause worsening of symptoms in some individuals. (Good thoughts rarely kill, though nocebos do exist.)
    3. Long Duration: Changes associated with the treatment endure for weeks, months, or years.
    4. Dose-dependence: Extent of changes reflect an accumulation of doses (cumulation and carry-over effects)
    5. Time-dependence: Changes occur in response to a manipulated time-line. Symptom changes do not emerge before or long after treatment is complete, for instance. (time-effect curves)

    Neurofeedback meets each of the above criteria for ADHD and epilepsy and other disorders, but most of this information -- such as long duration and dose dependence -- is in the clinical record only, unpublished, and therefore unavailable to our critics. I can see a research program, or a dozen, focused on these five criteria.

    One day, I see myself sitting down for a neurofeedback training session, strapping on the electrodes, and saying, "I hope the placebo effect is strong today" -- and be mocking our rocky past.

    -DK

     


    News & Reviews NEW BOOKS

    The Mind and the Brain : Neuroplasticity and the Power of Mental Force
    by Jeffrey M. Schwartz, Sharon Begley;
    Schwartz pioneered the use of PET in studying OCD. --www.amazon.com/exec/obidos/ASIN/0060393556/top100

    Principles and Practice of Sleep Medicine
    by Meir H. Kryger, et al
    Encompasses pathophysiology, diagnosis, and treatment of disorders resulting from disruptions of sleep-wake cycles and circadian rhythm. --www.amazon.com/exec/obidos/ASIN/0721676707/top100

    The Body Remembers: The Psychophysiology of Trauma and Trauma Treatment
    by Babette Rothschild
    Somatic memory of trauma experienced is discussed with case studies. --www.amazon.com/exec/obidos/ASIN/0393703274/top100

    Wider than the Sky: The Phenomenal Gift of Consciousness
    by Gerald M. Edelman
    How do neurons give rise to subjectivity? From Nobel Laureate. Pertinent findings of modern neuroscience --www.amazon.com/exec/obidos/ASIN/0300102291/top100

    Drugs, Behavior, and Modern Society
    by Charles F. Levinthal
    Controversies surrounding drug use and abuse with a focus on health and prevention. --www.amazon.com/exec/obidos/ASIN/0205323669/top100

    The Epidemic: The Rot of American Culture, Absentee and Permissive Parenting...
    by Robert Shaw
    Definitely the author doesn't pull any punches: "(Spoiled) children are not an aberration. They are the natural outcome of the way we have been raising them," --www.amazon.com/exec/obidos/ASIN/0060011831/top100

    Adult Children of Alcoholics: Expanded Edition
    by Janet Woititz
    Advice and information for adult children of dysfunctional families --www.amazon.com/exec/obidos/ASIN/1558741127/top100

     


    JOURNAL PAPERS

    Stimulant treatment over five years: adherence, effectiveness, and adverse effects. : Psychostimulants improve ADHD symptoms but adverse effects persist. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15100562

    Use of the Calmset 3 biofeedback/relaxation system in nocturnal bruxism. : Single patient exhibited fewer bruxing episodes following treatment, which were sustained at 6 month followup. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15208977

    The medial temporal lobe : Reviews function of MTL. No simple dichotomies for it versus hippocampus were found (e.g., and associative versus nonassociative memory, episodic versus semantic memory) www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15217334

    Low emotional intelligence as a predictor of substance-use problems. : Poorer coping predicted drug-related problems, but not alcohol-related problems. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15237864

    Neuropsychology of adults with ADHD: a meta-analytic review. : ADHD adults exhibit europsychological deficits in attention, behavioral inhibition, and memory www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15291727

    Efficacy of treatment for child and adolescent traumatic stress. : Meta-analysis of 8 studies found treatment for traumatic stress led to greater improvement than either no treatment or routine community care. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15289252

    128-Channel EEG Source Imaging in Epilepsy: Clinical Yield and Localization Precision. : Evaluated feasibility, clinical yield, and localization precision of high-resolution EEG source imaging of interictal epileptic activity. Foci was localized in 93% of patients, 79% exactly. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15284597

    Abnormal EEG synchronisation in heavily drinking students. : Heavily drinking students had more synchronisation in theta and gamma bands during eyes closed, both with and without a task, interpreted as changes in hippocampal-neocortical connectivity. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15294207

    Concept of psychical trauma: A bridge in interdisciplinary space. : Recent neuroscience findings in emotion and memory are integrated with psychoanalysis and the concept of trauma. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15310427

    Perspectives on the estimation of effective connectivity from neuroimaging data. : Discusses model in use with event-related fMRI to estimate connectivity across the brain. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15319514

    Does sleep or sleep deprivation increase epileptiform discharges? : Sleep deprivation does not increase the yield of epileptic discharge in pediatric EEGs. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15342836

    Neuroscience research on the addictions : Advances in neuroimaging will eventually allow pre-onset addiction and other frightening invasions of privacy. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15345277

     


     

    Events & Locations

    Upcoming Courses

    A Pathway to Brain Regulation - Neurofeedback helps improve neuroregulation. It's used by health care professionals for ADHD, depression, anxiety disorders, LD, mood disorders, and behavioral problems. This 4-day course, Neurofeedback in a Clinical Practice, provides the basis for using Neurofeedback clinically. - *28 CEs

      4-Day Comprehensive Course Dates
    • Raleigh NC Nov 11-14
    • Los Angeles CA Dec 9-12
    • Dallas TX Jan 13-16
    • Orlando FL Feb 24-27
    • Phoenix AZ Mar 10-13
    • Boston MA Apr 7-10

    Our course is a hands-on experience right from the start. Attendees consistently say this format is a very good way to learn Neurofeedback.

    "Neurofeedback should be viewed as one of the three essential or primary forms of intervention - psychotherapy, psychopharmacology, and Neurofeedback. In my experience, neurofeedback is every bit as important and powerful as the other two forms of treatment." - Dr. Laurence Hirshberg of Brown University Medical School, a psychologist specializing in Developmental Disorders and Autism.

    Contact Karie Kramer, our training coordinator, for more information 818-789-3456 ext 847 or see www.eegspectrum.com/Training

    *EEG Spectrum International, Inc. is approved by the APA to offer continuing education to psychologists. ESII maintains responsibility for the program.

    Conferences for Neurofeedback Clinicians & Researchers

    CONFERENCELOCATIONDATES
    iSNR - http://www.isnr.orgFt LauderdaleAug 26-29


     

    Last Word

    Faulty Foresight

    The political season is nearly over, thank goodness: only 15 polling days left! The debates were filled with predictions, as they are every election year. I'm reminded of George W Bush's comment in the 2000 debates "I would be very careful about using our troops as nation builders." (Oct 3, 2000). Or Cheney's "My belief is we will in fact be greeted as liberators (by the Iraqi people)." (3/16/03) or Secretary of Defense Donald Rumsfeld's "We know where (the weapons) are. They're in the area around Tikrit and Baghdad and East, West, North and South somewhat." (3/3/03) or his "It is not knowable how long that conflict would last. It could last, you know, six days, six weeks, I doubt six months." (2/7/03). Politicians are poor prognosticators -- but scientists and business people aren't much better.

    Ironically, those well-situated in scientific or cultural fields are often the last to recognize change. Ripples must become swells before makers and shakers of the previous paradigm take notice, and by then, it is usually too late to respond or assist.

    Here are a number of erroneous predictions, preceded by a few comments about prognostication itself:

    Recently, an adolescent with uncontrolled seizures had his corpus callosum partially severed to stop the seizures. Unfortunately, the procedure did not have the intended result. A vagal stimulator was then implanted. Again, the seizures continued. Since the neurologists and surgeons had no other remedy in mind, the mother asked whether neurofeedback might be tried. The neurologist was not caught at a loss for words: "Too experimental," he said.

    Not exactly a prediction, but short-sighted nonetheless.